Home Newsfeeds Needham Maintains Buy on Apellis Pharmaceuticals, Maintains $80 Price Target

Needham Maintains Buy on Apellis Pharmaceuticals, Maintains $80 Price Target

Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $80 price target.

byBenzinga Newsdesk

February 22, 2023

1 minute read

Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $80 price target.

JP Morgan Downgrades KeyCorp to Underweight, Lowers Price Target to $17

By Benzinga Newsdesk

December 13, 9:38 AM

JP Morgan analyst Steven Alexopoulos downgrades KeyCorp (NYSE:KEY) from Neutral to Underweight and lowers the price target from $18.5 to $17.

KEY

Movers
News

What’s Going On With Fisker Stock?

By Adam Eckert

September 7, 10:04 AM

Fisker Inc (NYSE: FSR) shares are flat Thursday morning after the company provided a production update.

FSR

Chevron’s Strategic Advances In Oil Production Overshadowed By Q1 Revenue Miss

By Akanksha Bakshi

April 26, 8:25 AM

Oil giant Chevron reported Q1 2024 revenues of $48.716B, down 4.1% YoY, beating EPS estimates. U.S. upstream earnings increased, while international upstream and downstream earnings fell. CVX returned $6B to shareholders and declared a quarterly dividend of $1.63 per share.

CVX